Previous 10 | Next 10 |
Gainers: ProQR Therapeutics (PRQR) +47%.Cellect Biotechnology (APOP) +47%.Houston Wire & Cable (HWCC) +38%.GameStop (GME) +29%.Koss (KOSS) +28%.Cinedigm (CIDM) +28%.F-star Therapeutics (FSTX) +26%.FreightCar America (RAIL) +24%.Polar Power (POLA) +20%.Immutep (IMMP) +20%.Losers:...
Cyclo Therapeutics (CYTH) announces positive topline data from its Phase 1/2 clinical trial, which showed promising safety and efficacy results for Trappsol Cyclo in the treatment of Niemann-Pick Disease type C1, a rare genetic disease causing cholesterol accumulation in cells,...
(CYTH): FY GAAP EPS of -$5.60 misses by $3.85.Revenue of $0.9M (-10.9% Y/Y) misses by $0.31M.Shares +7.08% PM.10KPress Release For further details see: EPS misses by $3.85, misses on revenue
- Multiple value-driving milestones expected throughout 2021 - Trappsol ® Cyclo™ Niemann Pick Disease Type C (NPC) clinical program on track to imminently report topline results from Phase 1/2 study - Company expects to commence enrollment in pivotal Ph...
Cyclo Therapeutics (CYTH) appoints Russ Belden as acting Chief Commercial Officer.Mr. Belden is a commercialization leader with over 33 years of senior leadership experience in the biotechnology industry, specializing in strategic marketing, sales management, sales training, an...
Preeminent biotechnology commercialization leader with over 33 years of industry experience, including 16 years at Genentech with a pivotal role in commercializing products across multiple therapeutic areas Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeut...
Cyclo Therapeutics (CYTH) gets positive opinion from the Paediatric Committee ((PDCO)) of the European Medicines Agency ((EMA)) on its agreement with the proposed Paediatric Investigation Plan ((PIP)) for Trappsol Cyclo, currently in development for the treatment of Niemann-Pic...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today ...
Cyclo Therapeutics (CYTH) announces that the last patient completed their last visit in the Phase 1/2 study evaluating Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously to patients with Niemann-Pick Disease Type C1 ((NPC1)), ...
Topline results from Phase 1/2 study on track for March 2021 Individual and cumulative data seen to-date show Trappsol ® Cyclo™ to be well tolerated with a favorable safety profile for all dose groups and to have encouraging signals in efficacy Pivotal ...
News, Short Squeeze, Breakout and More Instantly...
Cyclo Therapeutics Inc. Company Name:
CYTH Stock Symbol:
NASDAQ Market:
Cyclo Therapeutics Inc. Website:
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...
NEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. “During fiscal 2024, we have continued to develop our existing portfolio while ...